Updates in diagnosis and management of ebola hemorrhagic fever

Journal of Research in Medical Sciences

Volumn 21, Issue 6, 2016, Pages

  El Sayed, Salah Mohamed ^a,b   Abdelrahman, Ali A ^a   Ozbak, Hani Adnan ^a   Hemeg, Hassan Abdullah ^a   Kheyami, Ali Mohammed ^c   Rezk, Nasser ^a   El Ghoul, Mohamed Baioumy ^d   Nabo, Manal Mohamed Helmy ^e,f   Athy, Yasser Mohamed ^g  

^a TAIBAH UNIVERSITY   (Saudi Arabia)

^b SOHAG UNIVERSITY   (Egypt)

^c Molecular Virology Unit   (Saudi Arabia)

^d Uhud General Hospital   (Saudi Arabia)

^e Sohag University   (Egypt)

^f Maternity and Children Hospital ^*  (Saudi Arabia)

^g MINISTRY OF HEALTH   (Egypt)

Author keywords

Ebola hemorrhagic fever; Filoviruses; Fruit bats; Pathogenesis; Reverse transcription polymerase chain reaction

Indexed keywords

ANTICOAGULANT AGENT; FAVIPIRAVIR; LAMIVUDINE;

APOPTOSIS; BLOOD TRANSFUSION; CYTOKINE PRODUCTION; DISSEMINATED INTRAVASCULAR CLOTTING; EBOLA HEMORRHAGIC FEVER; ENZYME LINKED IMMUNOSORBENT ASSAY; FATALITY; FILOVIRUS; GASTROINTESTINAL HEMORRHAGE; HUMORAL IMMUNITY; LIVER NECROSIS; LYMPHOCYTE DEPLETION; MACULOPAPULAR RASH; MORTALITY RATE; OXIDATIVE STRESS; PATHOGENESIS; POST EXPOSURE PROPHYLAXIS; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEASONAL VARIATION; SIGNAL TRANSDUCTION; SKIN ABRASION; VIRUS TRANSMISSION;

EID: 84989355084     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: 10.4103/1735-1995.192500     Document Type: Review

References (100)

1. Hartman AL, Bird BH, Towner JS, Antoniadou ZA, Zaki SR, Nichol ST. Inhibition of IRF‑3 activation by VP35 is critical for the high level of virulence of Ebola virus. J Virol 2008;82:2699‑704.
2. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 2010;4. pii: E837.
3. Choi WY, Hong KJ, Hong JE, Lee WJ. Progress of vaccine and drug development for Ebola preparedness. Clin Exp Vaccine Res 2015;4:11‑6.
4. WHO Ebola Response Team. Ebola virus disease in West Africa – The first 9 months of the epidemic and forward projections. N Engl J Med 2014;371:1481‑95.
5. Chippaux JP. Outbreaks of Ebola virus disease in Africa: The beginnings of a tragic saga. J Venom Anim Toxins Incl Trop Dis 2014;20:44.
6. Ascenzi P, Bocedi A, Heptonstall J, Capobianchi MR, Di Caro A, Mastrangelo E, et al. Ebolavirus and marburgvirus: Insight the filoviridae family. Mol Aspects Med 2008;29:151‑85.
7. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011;377:849‑62.
8. Groseth A, Marzi A, Hoenen T, Herwig A, Gardner D, Becker S, et al. The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog 2012;8:e1002847.
9. Feldmann H, Jones SM, Schnittler HJ, Geisbert T. Therapy and prophylaxis of Ebola virus infections. Curr Opin Investig Drugs 2005;6:823‑30.
10. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 1409‑48.
11. Siegert R, Shu HL, Slenczka W, Peters D, Müller G. On the etiology of an unknown human infection originating from monkeys. Dtsch Med Wochenschr 1967;92:2341‑3.
12. Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, Nichol ST, et al. Discovery of swine as a host for the Reston ebolavirus. Science 2009;325:204‑6.
13. Groseth A, Feldmann H, Strong JE. The ecology of Ebola virus. Trends Microbiol 2007;15:408‑16.
14. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, MuyembeTamfum JJ, et al. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis 2009;9:723‑8.
15. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005;438:575‑6.
16. Pourrut X, Délicat A, Rollin PE, Ksiazek TG, Gonzalez JP, Leroy EM. Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species. J Infect Dis 2007;196 Suppl 2:S176‑83.
17. Towner JS, Amman BR, Sealy TK, Carroll SA, Comer JA, Kemp A, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 2009;5:e1000536.
18. Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, Ksiazek TG, et al. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 1996;2:321‑5.
19. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003;163:2347‑70.
20. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007;196 Suppl 2:S142‑7.
21. Hewlett BS, Amola RP. Cultural contexts of Ebola in Northern Uganda. Emerg Infect Dis 2003;9:1242‑8.
22. Hewlett BS, Epelboin A, Hewlett BL, Formenty P. Medical anthropology and Ebola in Congo: Cultural models and humanistic care. Bull Soc Pathol Exot 2005;98:230‑6.
23. Kibadi K, Mupapa K, Kuvula K, Massamba M, Ndaberey D, Muyembe-Tamfum JJ, et al. Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J Infect Dis 1999;179 Suppl 1:S13‑4.
24. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: A study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis 1999;179 Suppl 1:S87‑91.
25. Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P, Kerstiëns B, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis 1999;179 Suppl 1:S76‑86.
26. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International study team. Bull World Health Organ 1978;56:247‑70.
27. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978;56:271-93.
28. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 2010;375:1896-905.
29. Georges-Courbot MC, Sanchez A, Lu CY, Baize S, Leroy E, Lansout-Soukate J, et al. Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon. Emerg Infect Dis 1997;3:59-62.
30. Jaax NK, Davis KJ, Geisbert TJ, Vogel P, Jaax GP, Topper M, et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996;120:140-55.
31. Ryabchikova EI, Kolesnikova LV, Luchko SV. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 1999;179 Suppl 1:S199-202.
32. Baskerville A, Fisher-Hoch SP, Neild GH, Dowsett AB. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol 1985;147:199-209.
33. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003;188:1618-29.
34. Isaäcson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis 2001;33:1707-12.
35. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007;35:2191-5.
36. Murphy FA. Pathogenesis of Ebola virus infection. In: Pattyn SR, editor. Ebola Virus Haemorrhagic Fever. Amsterdam: Elsevier/ North-Holland; 1978. p. 43-59.
37. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW. Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol 2004;17:390-400.
38. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: Evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003;163:2371-82.
39. Geisbert TW, Jaax NK. Marburg hemorrhagic fever: Report of a case studied by immunohistochemistry and electron microscopy. Ultrastruct Pathol 1998;22:3-17.
40. Zaki SR, Goldsmith CS. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 1999;235:97-116.
41. Baize S, Leroy EM, Mavoungou E, Fisher-Hoch SP. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis 2000;5:5-7.
42. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud‑Soukate J, Debré P, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus‑infected patients. Nat Med 1999;5:423‑6.
43. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, Negley D, et al. Ebola and Marburg viruses replicate in monocyte‑derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003;188:1630‑8.
44. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, Rollin PE. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: Cellular responses, virus load, and nitric oxide levels. J Virol 2004;78:10370‑7.
45. Yaddanapudi K, Palacios G, Towner JS, Chen I, Sariol CA, Nichol ST, et al. Implication of a retrovirus‑like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J 2006;20:2519‑30.
46. Volchkov VE, Blinov VM, Netesov SV. The envelope glycoprotein of Ebola virus contains an immunosuppressive‑like domain similar to oncogenic retroviruses. FEBS Lett 1992;305:181-4.
47. Chepurnov AA, Tuzova MN, Ternovoy VA, Chernukhin IV. Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125‑kDa GP viral protein. Immunol Lett 1999;68:257‑61.
48. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB, et al. Markedly elevated levels of interferon (IFN)‑gamma, IFN‑alpha, interleukin (IL)‑2, IL‑10, and tumor necrosis factor‑alpha associated with fatal Ebola virus infection. J Infect Dis 1999;179 Suppl 1:S188-91.
49. Harcourt BH, Sanchez A, Offermann MK. Ebola virus selectively inhibits responses to interferons, but not to interleukin‑1beta, in endothelial cells. J Virol 1999;73:3491‑6.
50. Basler CF, Wang X, Mühlberger E, Volchkov V, Paragas J, Klenk HD, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 2000;97:12289‑94.
51. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Mühlberger E, Bray M, et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 2003;77:7945‑56.
52. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 2006;80:5156‑67.
53. Okware SI, Omaswa FG, Zaramba S, Opio A, Lutwama JJ, Kamugisha J, et al. An outbreak of Ebola in Uganda. Trop Med Int Health 2002;7:1068‑75.
54. Eichner M, Dowell SF, Firese N. Incubation period of ebola hemorrhagic virus subtype zaire. Osong Public Health Res Perspect 2011;2:3‑7.
55. Pourrut X, Kumulungui B, Wittmann T, Moussavou G, Délicat A, Yaba P, et al. The natural history of Ebola virus in Africa. Microbes Infect 2005;7:1005‑14.
56. Olival KJ, Islam A, Yu M, Anthony SJ, Epstein JH, Khan SA, et al. Ebola virus antibodies in fruit bats, bangladesh. Emerg Infect Dis. 2013;19:270-3.
57. Pourrut X, Souris M, Towner JS, Rollin PE, Nichol ST, Gonzalez JP, et al. Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infect Dis 2009;9:159.
58. Hayman DT, Emmerich P, Yu M, Wang LF, Suu-Ire R, Fooks AR, et al. Long‑term survival of an urban fruit bat seropositive for Ebola and Lagos bat viruses. PLoS One 2010;5:e11978.
59. Hayman DT, Yu M, Crameri G, Wang LF, Suu-Ire R, Wood JL, et al. Ebola virus antibodies in fruit bats, Ghana, West Africa. Emerg Infect Dis 2012;18:1207‑9.
60. Smith CE, Simpson DI, Bowen ET, Zlotnik I. Fatal human disease from vervet monkeys. Lancet 1967;2:1119‑21.
61. Negredo A, Palacios G, Vázquez-Morón S, González F, Dopazo H, Molero F, et al. Discovery of an ebolavirus-like filovirus in europe. PLoS Pathog 2011;7:e1002304.
62. Kuhn JH, Bào Y, Bavari S, Becker S, Bradfute S, Brauburger K, et al. Virus nomenclature below the species level: A standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol 2014;159:1229‑37.
63. Formenty P, Boesch C, Wyers M, Steiner C, Donati F, Dind F, et al. Ebola virus outbreak among wild chimpanzees living in a rain forest of Côte d’Ivoire. J Infect Dis 1999;179 Suppl 1:S120‑6.
64. Johnson BK, Wambui C, Ocheng D, Gichogo A, Oogo S, Libondo D, et al. Seasonal variation in antibodies against Ebola virus in Kenyan fever patients. Lancet 1986;1:1160.
65. Pinzon JE, Wilson JM, Tucker CJ, Arthur R, Jahrling PB, Formenty P. Trigger events: Enviroclimatic coupling of Ebola hemorrhagic fever outbreaks. Am J Trop Med Hyg 2004;71:664‑74.
66. Gautier-Hion A, Michaloud G. Are figs always keystone resources for tropical frugivorous vertebrates? A test in Gabon. Ecology 1989;70:1826‑33.
67. Pattyn SR. The epidemic of hemorrhagic fever in Zaire (August‑November 1976) and its implications. Verh K Acad Geneeskd Belg 1983;45:201‑25.
68. Pattyn, SR. Ebola virus haemorrhagic fever. Amsterdam, North‑Holland: Elsevier; 1978.
69. Peters CJ, LeDuc LW. Ebola: The virus and the disease. J Infect Dis 1999;179 Suppl 1:S1-288.
70. Feldmann H, Geisbert T, Kawaoka Y. Filoviruses: Recent advances and future challenges. J Infect Dis 2007;196 Suppl 2:S129‑30.
71. Baron RC, McCormick JB, Zubeir OA. Ebola virus disease in Southern Sudan: Hospital dissemination and intrafamilial spread. Bull World Health Organ 1983;61:997‑1003.
72. Carod-Artal FJ. Illness due the Ebola virus: Epidemiology and clinical manifestations within the context of an international public health emergency. Rev Neurol 2015;60:267-77.
73. Report of an International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978;56:271‑93.
74. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: Clinical observations in 103 patients. J Infect Dis 1999;179 Suppl 1:S1‑7.
75. MacNeil A, Farnon EC, Wamala J, Okware S, Cannon DL, Reed Z, et al. Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis 2010;16:1969‑72.
76. Roddy P, Howard N, Van Kerkhove MD, Lutwama J, Wamala J, Yoti Z, et al. Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007‑2008. PLoS One 2012;7:e52986.
77. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007;196 Suppl 2:S390‑9.
78. Fhogartaigh CN, Aarons E. Viral haemorrhagic fever. Clin Med (Lond) 2015;15:61‑6.
79. Barry M, Traoré FA, Sako FB, Kpamy DO, Bah EI, Poncin M, et al. Ebola outbreak in Conakry, Guinea: Epidemiological, clinical, and outcome features. Med Mal Infect 2014;44:491‑4.
80. Martin P, Laupland KB, Frost EH, Valiquette L. Laboratory diagnosis of Ebola virus disease. Intensive Care Med 2015;41:895‑8.
81. Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, Swanepoel R, et al. Clinical virology of Ebola hemorrhagic fever (EHF): Virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999;179 Suppl 1:S177‑87.
82. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, et al. A case of severe Ebola virus infection complicated by gram‑negative septicemia. N Engl J Med 2014;371:2394‑401.
83. Liang H, Zhou Z, Zhang S, Zen K, Chen X, Zhang C. Identification of Ebola virus microRNAs and their putative pathological function. Sci China Life Sci 2014;57:973‑81.
84. Clark DV, Jahrling PB, Lawler JV. Clinical management of filovirus‑infected patients. Viruses 2012;4:1668‑86.
85. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. Lancet 2003;362:1953‑8.
86. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, Grolla A, et al. Effective post‑exposure treatment of Ebola infection. PLoS Pathog 2007;3:e2.
87. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989;11 Suppl 4:S750-61.
88. Ignatyev G, Steinkasserer A, Streltsova M, Atrasheuskaya A, Agafonov A, Lubitz W. Experimental study on the possibility of treatment of some hemorrhagic fevers. J Biotechnol 2000;83:67-76.
89. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario‑DiCaprio K, et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 2006;193:1650‑7.
90. Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, et al. Gene‑specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006;2:e1.
91. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, et al. Protection against filovirus diseases by a novel broad‑spectrum nucleoside analogue BCX4430. Nature 2014;508:402‑5.
92. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T‑705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100:446‑54.
93. Zhang Y, Li D, Jin X, Huang Z. Fighting Ebola with ZMapp: Spotlight on plant‑made antibody. Sci China Life Sci 2014;57:987‑8.
94. Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, et al. A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed 2013;3:337‑52.
95. Alemi M, Sabouni F, Sanjarian F, Haghbeen K, Ansari S. Anti‑inflammatory effect of seeds and callus of Nigella sativa L. extracts on mix glial cells with regard to their thymoquinone content. AAPS PharmSciTech 2013;14:160‑7.
96. Shuid AN, Mohamed N, Mohamed IN, Othman F, Suhaimi F, Mohd Ramli ES, et al. Nigella sativa: A potential antiosteoporotic agent. Evid Based Complement Alternat Med 2012;2012:696230.
97. El Mezayen R, El Gazzar M, Nicolls MR, Marecki JC, Dreskin SC, Nomiyama H. Effect of thymoquinone on cyclooxygenase expression and prostaglandin production in a mouse model of allergic airway inflammation. Immunol Lett 2006;106:72‑81.
98. Chehl N, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA. Anti‑inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford) 2009;11:373‑81.
99. Majdalawieh AF, Hmaidan R, Carr RI. Nigella sativa modulates splenocyte proliferation, Th1/Th2 cytokine profile, macrophage function and NK anti‑tumor activity. J Ethnopharmacol 2010;131:268‑75.
100. Yildiz F, Coban S, Terzi A, Ates M, Aksoy N, Cakir H, et al. Nigella sativa relieves the deleterious effects of ischemia reperfusion injury on liver. World J Gastroenterol 2008;14:5204‑9.